The third and final portion of Bryant’s exclusive video interview with PharmTech ® deals with the processes known as human-in ...

Our data show that global pharma M&A is becoming more selective and strategically targeted. While North America remains the ...

Next-generation biologics, such as bispecifics, fusion proteins, and multi-specifics, have multiple functionalities that ...

Digital GMP expectations are increasing, driven by Annex 11 and Annex 22, necessitating robust lifecycle management, data ...

Felix Gonzalez, FounderNest, offers a data-driven view of where pharma consolidation is occurring, where capital is being deployed, and how regional M&A strategies differ.

In an expansion of his written three-part series for PharmTech, Jason Bryant of ArisGlobal explains the interplay between autonomy and accountability that is essential for AI agents assisting the ...

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

Autonomy is not a binary option, Bryant said in the first part of this video interview with PharmTech ®, and can work in ...

In an expansion of his written three-part series for PharmTech, Jason Bryant of ArisGlobal explains the interplay between ...

The top 10 PharmTech videos of the year cover advanced therapies, high-concentration biologics, major mergers and ...

The year 2025 was defined by escalating global trade tensions that fundamentally reshaped the pharmaceutical supply chain, ...

From a global regulatory perspective, Cytokinetics is expanding its footprint rapidly. The drug received approval in China on ...